Pro-life group says Trump admin didn't give key abortion drug commitments before Overton FDA nomination pulled
A leading pro-life group said it opposed advancing Heidi Overton's nomination to lead the Food and Drug Administration without commitments from the Trump administration on abortion drug policy.
- Baptist said the group wants the next FDA nominee to commit to ending mail-order access to abortion drugs authorized under the Biden administration and changing how the agency studies the safety of those pills.
- WOMAN WHO SAYS ABORTION PILLS NEARLY KILLED HER URGES RFK JR TO ACT AS GROUP DEMANDS MAIL-ORDER CRACKDOWN Overton also previously served as vice chair and chief policy officer at the America First Policy Institute, a conservative think tank, where she criticized expanded access to abortion pills in a 2023 policy brief.
- The White House pulled Overton’s nomination to lead the FDA earlier this week, one day before a Senate committee vote.
Anthony Pro-Life America, said his group asked the Senate to hold up Overton’s confirmation until it received "firm commitments" from the administration on two fronts regarding abortion drug policy.
- Those states can’t meaningfully enforce their laws while this nationwide policy is in place." WHITE HOUSE PULLS TRUMP'S FDA PICK HEIDI OVERTON ON EVE OF SENATE PANEL VOTE "Under the Biden-era policy, anybody can obtain these drugs online and receive them through the mail," he continued.
- "I believe she would have had the votes to pass out of committee and pass the full Senate." Baptist said he did not know whether the White House was concerned about pro-life votes or other constituencies but thinks….
- The White House said Overton lacked the votes on Capitol Hill and pulled her nomination, although Sen.
- President Donald Trump picked Overton, a physician and White House advisor, in August to succeed Marty Makary, who resigned from the position in May.
- We have asked for more robust data because significant information is currently lacking, including transparency into the agency’s methodology and an invitation for outside experts who have studied this drug over the last few decades." "This is something that should be bipartisan.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →